Orbital Therapeutics is building a first-in-kind RNA platform that integrates established and emerging RNA technologies, delivery mechanisms, data science and automation to broaden the reach of RNA medicines. The company is focused on next-generation vaccines, immunomodulation, and protein replacement, and seeks to extend the durability of RNA therapeutics while expanding delivery to a wide range of cell types and tissues. Orbital excludes small interfering RNA from its stated remit and emphasizes platform-driven discovery and development. The company describes itself as founded by experts in genetic medicine and RNA development and delivery. Recent corporate growth included executive hires to support development and operations. The financing announced will support expansion of the platform and portfolio toward patient-facing programs.

Total raised

$270M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2023